EPYC Human

Epiphycan Human Recombinant
Shipped with Ice Packs
In Stock

Description

Molecular Structure and Production

EPYC Human Recombinant is produced in HEK293 cells as a single glycosylated polypeptide chain containing 309 amino acids (residues 20-322) with a C-terminal 6x His-tag. Key characteristics include:

PropertySpecification
Molecular Mass35.5 kDa
Purity>95% (SDS-PAGE)
Biological Activity>60% adhesion support for Saos-2 cells
Storage10% glycerol in PBS (pH 7.4)
StabilizationRequires 0.1% HSA/BSA for long-term storage

This recombinant form retains functional properties, enabling studies on cell-matrix interactions and signaling pathways .

Biological Functions and Mechanisms

EPYC regulates extracellular matrix dynamics through:

  • Collagen Fibrillogenesis: Binds collagen fibrils to modulate tissue architecture .

  • Growth Factor Modulation: Interacts with TGF-β and BMPs to influence chondrogenesis and osteogenesis .

  • Cell Adhesion/Proliferation: Supports osteosarcoma cell adhesion via integrin-mediated pathways .

Dysregulation is linked to osteoarthritis, high myopia, and cancer progression .

Role in Pancreatic Cancer: Key Findings

Recent studies identify EPYC as an oncogenic driver in pancreatic cancer (PC):

Table 1: EPYC in Pancreatic Cancer (TCGA/GEO Data Analysis)

ParameterResult
Expression in PC Tumors3.8-fold increase vs. normal tissue
Survival CorrelationHigh EPYC = 34% lower 5-year survival
Pathway ActivationPI3K-AKT (p-AKT elevation)
Functional ImpactPromotes proliferation, migration, and tumor growth in vitro/in vivo

Mechanistic Insights:

  • Knockdown of EPYC reduces PC cell viability by 40–60% (CCK8/EdU assays) .

  • Suppresses E-cadherin while upregulating Vimentin and PCNA, indicating epithelial-mesenchymal transition (EMT) promotion .

  • Subcutaneous xenograft models show 50% smaller tumors with EPYC silencing .

Therapeutic and Diagnostic Potential

EPYC’s dual role as a biomarker and therapeutic target is under exploration:

  • Diagnostic Utility: Elevated serum EPYC levels correlate with advanced PC stages (AUC = 0.87 in ROC analysis) .

  • Therapeutic Strategies:

    • Small-molecule inhibitors targeting EPYC-PI3K-AKT axis.

    • Antibody-drug conjugates (ADCs) against EPYC-overexpressing tumors .

Technical Applications in Research

EPYC Human is utilized in:

  • Cell Adhesion Assays: Quantified via Saos-2 osteosarcoma cell adherence .

  • Matrix Remodeling Studies: Evaluated in 3D cartilage/organoid models .

  • High-Throughput Screening: For drug discovery targeting proteoglycan-driven cancers .

Future Directions

Ongoing research focuses on:

  • Resolving EPYC’s isoform-specific functions using cryo-EM and T2T genome assemblies .

  • Clinical validation of anti-EPYC therapies in Phase I trials for PC and osteoarthritis.

Product Specs

Description
Recombinant human EPYC protein, expressed in HEK293 cells, comprises a single glycosylated polypeptide chain of 309 amino acids (residues 20-322) with a molecular weight of 35.5 kDa. The protein includes a C-terminal 6-amino acid His-tag and is purified using proprietary chromatographic methods.
Physical Appearance
Clear, colorless, and sterile-filtered solution.
Formulation
The EPYC protein is provided at a concentration of 0.5 mg/ml in a solution containing 10% glycerol and Phosphate-Buffered Saline (pH 7.4).
Stability
For short-term storage (up to 4 weeks), the protein can be stored at 4°C. For extended storage, it is recommended to freeze the protein at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Repeated freezing and thawing cycles should be avoided.
Purity
The purity is determined to be greater than 95.0% by SDS-PAGE analysis.
Biological Activity
The biological activity is assessed to be greater than 60%. This determination is based on the protein's ability, when immobilized, to promote the adhesion of Saos-2 human osteosarcoma cells to plates coated with 1.25 µg/ml of human DSPG3 and 0.5 µg/ml of human fibronectin.
Synonyms

Epiphycan, SLRR3B, DSPG3, EPYC Dermatan sulfate proteoglycan 3, Proteoglycan-Lb, PG-Lb, Small chondroitin/dermatan sulfate proteoglycan, PGLB, epiphycan proteoglycan.

Source

HEK293 Cells.

Amino Acid Sequence

APTLESINYD SETYDATLED LDNLYNYENI PVDKVEIEIA TVMPSGNREL LTPPPQPEKA QEEEEEEEST PRLIDGSSPQ EPEFTGVLGP HTNEDFPTCL LCTCISTTVY CDDHELDAIP PLPKNTAYFY SRFNRIKKIN KNDFASLSDL KRIDLTSNLI SEIDEDAFRK LPQLRELVLR DNKIRQLPEL PTTLTFIDIS NNRLGRKGIK QEAFKDMYDL HHLYLTDNNL DHIPLPLPEN LRALHLQNNN ILEMHEDTFC NVKNLTYIRK ALEDIRLDGN PINLSKTPQA YMCLPRLPVG SLVHHHHHH.

Q&A

What is the EPYC gene and what is its role in human skeletal development?

The EPYC gene encodes Epiphycan, a small leucine-rich proteoglycan that plays a crucial role in cartilage extracellular matrix organization. Based on recent studies, EPYC is expressed during cartilage development and is particularly associated with articular cartilage phenotype . Notably, it appears to be down-regulated during the transition to hypertrophic chondrocytes, suggesting it maintains the pre-hypertrophic chondrocyte state in normal development.

Methodological approach: To investigate EPYC's role in skeletal development, researchers should employ a multi-faceted approach:

  • Gene expression analysis during different stages of chondrogenesis using qRT-PCR

  • Spatial localization studies using RNA in situ hybridization or immunohistochemistry

  • Functional studies using gene knockdown or overexpression in appropriate cell culture models

  • Correlation of EPYC expression with cartilage matrix production and quality

How is EPYC expression regulated during chondrocyte differentiation?

From available data, EPYC expression appears to be downregulated by T3 (triiodothyronine) treatment at day 69 of differentiation , suggesting hormonal regulation of its expression. This down-regulation occurs alongside other cartilage-specific genes including COL11A1, COL9A1, COL9A2, COL9A3, MATN1, LUM, COMP, and EDIL3 during the transition to hypertrophic chondrocytes.

Methodological approach:

  • Time-course experiments tracking EPYC expression during in vitro chondrocyte differentiation

  • Treatment studies with various hormones, growth factors, and cytokines to identify regulatory signals

  • Promoter analysis using reporter constructs to identify key regulatory elements

  • ChIP-seq analysis to identify transcription factors binding to the EPYC promoter region

  • Epigenetic profiling to identify DNA methylation or histone modification changes during differentiation

What are the most common experimental models used to study EPYC function?

Based on current research, induced pluripotent stem cells (iPSCs) differentiated toward chondrogenic lineage represent a valuable model system for studying EPYC function . This model allows researchers to recapitulate endochondral bone formation in vitro.

Methodological approach:

  • 3D pellet culture systems to promote chondrogenesis from iPSCs

  • Directed differentiation protocols that pass through developmental intermediates (primitive streak, paraxial mesoderm, somitic mesoderm, and sclerotome)

  • Manipulation of culture conditions to direct cells toward articular or growth plate cartilage phenotypes

  • Analysis of gene expression, histology, and functional assays to assess the impact of EPYC modulation

  • Comparison with primary chondrocyte cultures and tissue explants to validate findings

How can iPSC-derived models help in studying EPYC's role in cartilage development?

Recent research describes a method to direct iPSC-derived sclerotome to chondroprogenitors in 3D pellet culture, which can then be directed toward either articular chondrocytes or growth plate cartilage pathway . This system provides several advantages for studying EPYC function.

Methodological approach:

  • Generation of isogenic iPSC lines with EPYC mutations using CRISPR-Cas9 gene editing

  • Differentiation of modified and control iPSCs to compare phenotypic differences

  • Implementation of reporter systems to track EPYC expression in real-time

  • Co-culture experiments to investigate cell-cell interactions and paracrine signaling effects on EPYC expression

  • Application of mechanical stimulation or 3D bioprinting to create more physiologically relevant models

What methodologies are effective for analyzing EPYC expression during endochondral ossification?

Effective methodologies include comprehensive transcriptomic profiling to identify gene expression signatures during key developmental stages.

Methodological approach:

  • Bulk RNA-seq analysis of differentiated cell populations at defined timepoints

  • Single-cell RNA-seq to capture heterogeneity within differentiating populations

  • Spatial transcriptomics to preserve positional information within 3D constructs

  • Proteomics analysis to verify translation of EPYC mRNA and post-translational modifications

  • Integration of multi-omics data to place EPYC within developmental regulatory networks

Data from literature:
Gene expression analysis shows EPYC is strongly expressed during early chondrogenesis but downregulated during hypertrophic differentiation in response to T3 treatment .

How do EPYC gene mutations correlate with specific genetic skeletal disorders?

While specific correlations between EPYC mutations and skeletal disorders are not detailed in the current literature, the iPSC-derived model system "can be used to model genetic cartilage and bone disorders, and search for therapies" .

Methodological approach:

  • Whole exome/genome sequencing of patients with undiagnosed skeletal disorders

  • Variant filtering and prioritization focusing on cartilage-related genes including EPYC

  • Generation of patient-derived iPSCs containing naturally occurring EPYC mutations

  • Differentiation along chondrogenic lineage to observe phenotypic abnormalities

  • Gene correction experiments to establish causality

  • High-throughput drug screening to identify compounds that rescue mutant phenotypes

What are the challenges in achieving consistent EPYC knockdown using siRNA technology?

Commercial siRNA products targeting EPYC are available, such as "EPYC Human Pre-designed siRNA Set A" which contains designed siRNAs for the EPYC gene , suggesting siRNA technology is being used to study EPYC function.

Methodological approach to overcome challenges:

  • Optimization of transfection protocols specific for chondrocyte or chondroprogenitor cells

    • Testing different transfection reagents and conditions

    • Establishing electroporation parameters for high efficiency and low toxicity

  • Validation strategies:

    • qRT-PCR to verify mRNA knockdown efficiency

    • Western blotting or ELISA to confirm protein reduction

    • Functional assays to assess physiological impact

  • Control implementation:

    • Use of multiple siRNA sequences targeting different regions of EPYC

    • Inclusion of non-targeting control siRNAs

    • Rescue experiments with siRNA-resistant EPYC constructs

How does EPYC interact with other cartilage extracellular matrix molecules?

The research literature mentions EPYC alongside other key cartilage ECM molecules including collagens (COL2A1, COL11A1, COL9A1, etc.), aggrecan (ACAN), HAPLN1, and matrilins (MATN1, MATN3) .

Methodological approach:

  • Protein-protein interaction studies:

    • Co-immunoprecipitation followed by mass spectrometry

    • Proximity ligation assays in native cartilage tissue

    • Biolayer interferometry or surface plasmon resonance for binding kinetics

  • Structural analysis:

    • X-ray crystallography or cryo-EM of EPYC-ECM protein complexes

    • Molecular dynamics simulations to predict interaction domains

  • Functional interaction studies:

    • Coordinated gene knockdown experiments

    • Matrix assembly assays in vitro

    • Atomic force microscopy to assess mechanical properties of ECM with and without EPYC

What contradictions exist in the literature regarding EPYC's function in articular versus growth plate cartilage?

While the literature doesn't explicitly mention contradictions regarding EPYC's function in different cartilage types, they indicate differential expression between cartilage subtypes.

Methodological approach to resolve contradictions:

  • Comparative studies using both tissue types derived from the same iPSC line

  • Parallel differentiation protocols with specific modulators to direct cells toward articular or growth plate fates

  • Comprehensive phenotypic and functional analysis:

    • Histological assessment of matrix organization

    • Mechanical testing of tissue constructs

    • Gene expression profiling under various mechanical and biochemical stimuli

  • EPYC overexpression and knockdown studies in both cartilage subtypes to compare functional outcomes

  • Implementation of contradiction detection algorithms to identify inconsistent findings in the literature

How can EPYC expression patterns be used as markers for chondrocyte maturation in vitro?

The literature indicates that EPYC is among the markers that are downregulated during chondrocyte hypertrophy induced by T3 treatment .

Methodological approach:

  • Establishment of baseline expression profiles:

    • qRT-PCR or droplet digital PCR for precise quantification

    • Correlation with established maturation markers

  • Development of monitoring systems:

    • Reporter constructs with fluorescent proteins driven by EPYC promoter

    • High-content imaging platforms for real-time monitoring

  • Validation strategies:

    • Correlation of EPYC expression with matrix production and quality

    • Functional assessment of mechanical properties

    • Response to differentiation-modulating agents

Expression data table:

Differentiation StageEPYC ExpressionOther MarkersT3 Treatment Effect
Early chondrogenesisHighSOX9+, COL2A1+, ACAN+N/A
Pre-hypertrophicHighCOL2A1+, COL11A1+, MATN1+Downregulation
HypertrophicLowCOL10A1+, SP7+, VEGF+Further reduction

How can human sensemaking methodologies be applied to EPYC research in interdisciplinary contexts?

Based on research into human sensemaking in complex data environments, similar approaches can be applied to EPYC research .

Methodological approach:

  • Integration of ethnographic approaches with data science:

    • Observation of how researchers from different disciplines interpret EPYC data

    • Interviews with cartilage biologists, geneticists, and clinicians

  • Development of visual analytics tools specific to EPYC data:

    • Interactive visualization of expression data across developmental trajectories

    • Network representations of protein-protein interactions

  • Collaborative workshops bringing together experts from different fields:

    • Structured exercises to identify knowledge gaps

    • Co-development of research priorities

  • Implementation of machine learning approaches to identify patterns in EPYC data that may not be apparent to human researchers

What are the latest methodological advances in detecting and resolving contradictions in EPYC research?

Recent developments in contradiction detection could be applied to EPYC research, as shown by the CONTRADOC dataset methodology .

Methodological approach:

  • Application of natural language processing techniques to extract EPYC-related claims from literature

  • Implementation of contradiction detection algorithms to identify inconsistent findings

  • Meta-analysis frameworks to resolve contradictions based on:

    • Experimental methods used

    • Model systems (human vs. animal, in vitro vs. in vivo)

    • Temporal tracking of evolving understanding

  • Development of standardized reporting frameworks specific to cartilage research

  • Evaluation metrics similar to those used in CONTRADOC (accuracy, precision, recall, F1 scores)

How can extended perception, interaction, and cognition frameworks enhance EPYC research visualization?

The EPIC (Extended Perception, Interaction & Cognition) Research Group's approach to human-computer interaction could inform better visualization of complex EPYC expression data .

Methodological approach:

  • Development of holistic visualization systems that combine:

    • Spatial representation of EPYC expression in developing cartilage

    • Temporal progression of expression changes

    • Interactive elements allowing researchers to explore data relationships

  • Implementation of perception-action couplings in data exploration:

    • Haptic feedback systems for exploring 3D matrix structures

    • Augmented reality visualizations of molecular interactions

  • Design approaches that facilitate:

    • Break-through simplification of complex EPYC regulatory networks

    • Enhanced memorability of key expression patterns

    • Stronger sense of agency in data exploration experiences

Product Science Overview

Introduction

Epiphycan, also known as dermatan sulfate proteoglycan 3 (DSPG3), is a member of the small leucine-rich proteoglycan (SLRP) family. This protein plays a significant role in the extracellular matrix, particularly in skeletal tissues such as the growth plate of long bones, articular cartilage, and intervertebral discs . The recombinant form of human epiphycan is produced using advanced biotechnological methods, often involving expression in HEK293 cells .

Structure and Composition

Epiphycan is composed of a core protein with attached glycosaminoglycan (GAG) chains. The human recombinant form of epiphycan typically consists of a single, glycosylated polypeptide chain containing 309 amino acids, with a molecular mass of approximately 35.5 kDa . The protein is often fused to a His-tag at the C-terminus to facilitate purification .

Biological Functions

Epiphycan is involved in various biological processes, primarily related to tissue development, repair, and homeostasis. It interacts with collagen fibrils and other extracellular matrix proteins, regulating fibrillogenesis and influencing cell behavior and tissue organization . The unique structure of epiphycan allows it to bind to growth factors, cytokines, and other matrix proteins, thereby modulating their activity and availability .

Therapeutic Potential

The involvement of epiphycan in tissue development and repair has highlighted its potential as a therapeutic target. Research suggests that epiphycan may play a role in bone formation and the establishment of the ordered structure of cartilage through matrix organization . Its ability to interact with various growth factors and cytokines makes it a promising candidate for therapeutic interventions in conditions related to tissue damage and repair .

Production and Purification

Human recombinant epiphycan is produced using HEK293 cells, a widely used cell line for recombinant protein expression. The protein is purified using proprietary chromatographic techniques to achieve a purity greater than 95%, as determined by SDS-PAGE . The recombinant protein is typically formulated in a sterile, colorless solution containing glycerol and phosphate-buffered saline (PBS) at pH 7.4 .

Storage and Stability

For optimal stability, human recombinant epiphycan should be stored at 4°C if used within 2-4 weeks. For longer storage periods, it is recommended to freeze the protein at -20°C, with the addition of a carrier protein such as human serum albumin (HSA) or bovine serum albumin (BSA) to prevent degradation . It is important to avoid multiple freeze-thaw cycles to maintain the protein’s integrity and biological activity .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.